Dinaciclib - CAS# 779353-01-4 ram and several cancer lineages in

and several cancer lineages in vitro

NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice

InChiKey: FQTFHMSZCSUVEU-QRPNPIFTSA-N

Pretreatment of adipocytes with GF-109203X (5 microM) reduced GSK-3 activity in total cell lysates

Dinaciclib - CAS# 779353-01-4 ram and several cancer lineages inDinaciclib, also known as SCH727965, is a potent CDK inhibitor with potential antineoplastic activity. Dinaciclib selectively inhibits cyclin dependent kinases CDK1, CDK2, CDK5, and CDK9 activity in vitro with IC(50) values of 1, 1, 3, and 4 nmol L, respectively. Compared with flavopiridol, Dinaciclib exhibits superior activity with an improved therapeutic index. Dinaciclib induced regression of established solid tumors in a range of mouse models